Medtronic Inc. (NYSE:MDT) announced a pair of accomplishments for two of its cardiac treatment devices in Europe.
The Minneapolis-based medical device behemoth won CE Mark approval in the European Union for its CoreValve transcatheter aortic valve implantation system.
The company said the device, which has not yet been approved by the Food & Drug Administration for use in the U.S., increases the accuracy of the deployment of its CoreValve artificial aortic heart valve.
Medtronic also announced that doctors in the U.K. implanted the company’s Resolute Integrity drug-eluting coronary stent. It was the device’s first commercial use in Europe.
The company heralded the CE Mark approval for the new stent last week. The device’s new “continuous sinusoid technology” gives it significantly more deliverability than alternative stents when administered with the its MicroTrac delivery system, according to Medtronic.